Our round-up of financings in the biotech sector this week is led by BioAge Lab's filing of an initial public offering (IPO), with a placeholder target of $100 million, plus sizeable privat
Arsenal Biosciences has cleared an impressive $325 million from a third-round financing that will be used to fund clinical trials of its pipeline of CAR-T therapies, trying to break new gro
The BioIndustry Association (BIA) has asked new UK Chancellor Rachel Reeves for a nuanced approach to R&D tax credits in the upcoming budget, saying that the life sciences should not be
ReNeuron has become the latest UK biotech planning to cancel its listing on the AIM exchange, saying it has been unable to raise the capital it desperately needs to keep its business afloat
Further signs that the biotech initial public offering (IPO) market is picking up have come with a filing by MBX Biosciences, seeking around $100 million to take a hypoparathyroidism candid
Just a few months after raising $200 million in third-round financing, immunology specialist Zenas BioPharma has filed an initial public offering in the US seeking to add another $100 milli